Abstract 229P
Background
Cardiotoxicity (CTX) remains a clinically significant side effect of anti-HER2 therapies. Trastuzumab-related cardiotoxicity is most often manifested by an asymptomatic decrease in left ventricular ejection fraction (LVEF) and less often by clinical heart failure. The aim of this study is to demonstrate the trastuzumab cardiotoxicity with cardiac marker changing and efficacy of steroid and intravenous immunoglobulin (ivig) therapy in the prevention of cardiotoxicity.
Methods
Treatment Groups: Twenty-four adult male New Zealand white rabbits, weighing 2800–3500 g, were randomly divided into the following four groups (six rabbits in each group). These were randomly assigned to one of four groups. All of the rabbits were received trastuzumab treatment 10 mg/kg on day 1 then 7 mg / kg in the third week and 7mg / kg , in the sixth week. Then the treatment groups were received one of the following treatment regimens via intraperitoneal injection; Group 1: Intravenous immune globlun 1 gr/ kg (n = 6); Group 2: Steroid 1 mg/kg ( n = 6); Group 3: Saline solution 0.9 % ( n = 6); Group 4: Intravenous immune globlun 1 gr/ kg + steroid 1 mg/kg (n = 6). Biochemistry: On the first day , in the sixth week and in the eight week blood samples were taken measured for cardiac markers and trastuzumab level.On the first day of the study cardiac markers ; troponin I (TPI), high sensitive CRP(hCRP),myeloperoxidase (MPO)were calculated.In the sixth and eight week cardiac markers ( TPI, hCRP and MPO) and trastuzumab levels were calculated repeatly. All animal procedures were conducted in accordance with guidelines published by the Turkish Council on Animal Care.
Results
Biochemical parameters were measured and compared between the groups. No statistically significant difference was revealed between trastuzumab levels and cardiac marker levels in subgoups.
Conclusions
This is the first study to use steroid and ivig therapy to prevent trastuzumab cardiotoxicity in animal model. Intravenous immunglobulin was given because some studies demonstrated that ivig therapy increases antibody clearance. Immunosuppressive effects of intravenous immunoglobulin and steroids were also been considered. No definitive result was obtained.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.